Efficacy of MAGE-A4 long peptide as a universal immunoprevention cancer vaccine

The clinical application of peptide vaccines in tumor immunotherapy holds significant promise. Peptide-based tumor vaccines are currently subject to certain limitations in clinical trials, including the challenge of inducing a sustained response from CD4